A single ascending dose trial of PRS-080
Latest Information Update: 10 Jul 2017
Price :
$35 *
At a glance
- Drugs PRS 080 (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions
- Sponsors Pieris Pharmaceuticals
- 10 Jul 2017 New trial record
- 05 Jul 2017 The company plans to initiate this trial and dose subjects in the fourth quarter of 2017, according to a Pieris Pharmaceuticals media release.